{
    "Trade/Device Name(s)": [
        "SAFElife\u2122 Fentanyl Urine Home Test (Cassette)",
        "SAFElife\u2122 Fentanyl (FTY) Urine Test Cassette",
        "SAFElife\u2122 T-Dip Fentanyl Urine Home Test (Dip Card)",
        "SAFElife\u2122 T-Dip Fentanyl (FTY) Urine Test Panel"
    ],
    "Submitter Information": "Guangzhou Wondfo Biotech Co., Ltd.",
    "510(k) Number": "K241741",
    "Predicate Device Reference 510(k) Number(s)": [
        "K233417"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NGL"
    ],
    "Summary Letter Date": "June 13, 2024",
    "Summary Letter Received Date": "June 17, 2024",
    "Submission Date": "July 8, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Fentanyl",
        "Fentanyl (FTY)"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Competitive binding",
        "Lateral flow immunochromatographic assay"
    ],
    "Methodologies": [
        "Antigen-antibody immunochemistry",
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Test",
        "Cassette",
        "Dip Card",
        "Panel"
    ],
    "Document Summary": "FDA 510(k) summary for SAFElife Fentanyl urine home tests and panels for qualitative detection of fentanyl in human urine via lateral flow immunoassay",
    "Indications for Use Summary": "For qualitative detection of Fentanyl in human urine at a cutoff concentration of 1 ng/mL; intended for in vitro diagnostic and OTC use as a preliminary screening tool, with confirmatory analysis recommended by GC/MS or LC/MS-MS",
    "fda_folder": "Toxicology"
}